TB-500

Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study.

2026 · Preclinical

Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro.

2024 · Journal of chromatography. B, Analytical technologies in the biomedical and life sciences · Preclinical

TB-500 identity/formulation must be checked against this paper; includes fragment/analytical studies and animal work, not demonstrated human efficacy. Full-length thymosin beta-4 is not interchangeable.

TB500/TB1000 and SGF1000: A scientific approach for a better understanding of misbranded and adulterated drugs.

2023 · Drug testing and analysis · Preclinical

TB-500 identity/formulation must be checked against this paper; includes fragment/analytical studies and animal work, not demonstrated human efficacy. Full-length thymosin beta-4 is not interchangeable.

Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential.

2012 · Drug testing and analysis · Preclinical

TB-500 identity/formulation must be checked against this paper; includes fragment/analytical studies and animal work, not demonstrated human efficacy. Full-length thymosin beta-4 is not interchangeable.

Doping control analysis of TB-500, a synthetic version of an active region of thymosin β₄, in equine urine and plasma by liquid chromatography-mass spectrometry.

2012 · Journal of chromatography. A · Preclinical

TB-500 identity/formulation must be checked against this paper; includes fragment/analytical studies and animal work, not demonstrated human efficacy. Full-length thymosin beta-4 is not interchangeable.